Paxman had the opportunity to thank partners from across the Oncology speciality for their overwhelming support in implementation of their pioneering scalp cooling system throughout the US at the recent ASCO Annual Meeting in Chicago.

In the 5 years since FDA clearance was granted, Paxman Scalp Cooling is now a treatment option for patients at over 400 cancer treatment facilities in 40 states, with over 4,400 Paxman devices installed in over 60 markets internationally.

The pioneering system was used in the first-ever randomised multi-centre clinical trial to evaluate the benefits of modern scalp cooling, with findings published by JAMA and presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2017.   This paved the way for Paxman’s purposeful work in the US over the past 5 years. Paxman Scalp Cooling is now a standard of care at some of the most trusted medical institutions not only in the United States, but also around the world.

Richard Paxman, CEO of Paxman said: “Five years ago we took some of the most important steps in Paxman’s history, launching operations in the US following FDA clearance, which has since been expanded to help support a more diverse patient population.”

“Today we continue our vision to make scalp cooling more universally accessible to help reduce the risks of one of the most devastating side effects of chemotherapy. We’ve celebrated a number of proud moments in the last five years to help improve the lives of cancer patients around the world..”

Importantly in 2021, the American Medical Association (AMA) issued two separate CPT® Category III Codes for “mechanical scalp cooling”, 0662T and 0663T, subsequently the US Centers for Medicare & Medicaid Services (CMS) reassigned payment for scalp cooling for Medicare claims filed using CPT code 0662T. This treatment has been reassigned to New Technology APC 1520 with a National Average Payment of $1,850.50

Upwards of 400 locations that already have Paxman equipment installed across the United States are now able prepare for the possibility of increased payer reimbursement opportunities for Paxman Scalp Cooling treatment in compliance with the laws and rules governing provision of items and services reimbursable by private insurance and federal programs including Medicare or Medicaid.  To give patients and healthcare providers access to this new opportunity, Paxman have launched a new buy and bill business model along with first-class support services.

Paxman HUB support services will assist practices and patients with insurance benefit verification and prior authorization processes, and Paxman’s enhanced Patient Assistance Program (PAP) will allow many more patients to access scalp cooling.  For those who may not qualify for the PAP, Paxman will continue to work with financial assistance foundations ensuring that scalp cooling is an affordable option for all who want the chance to avoid the devastating side effect of cytotoxic-induced hair loss.